BRPI0415816A - composição, bactéria ou um preparado da mesma, método para detectar a presença de um patógeno de a/e em uma amostra, método para provocar uma resposta imunológica contra um patógeno de a/e ou um componente do mesmo em um animal, método para reduzir a colonização de um patógeno de a/e em um animal, método para reduzir a disseminação de um patógeno de a/e em um animal, método para o tratamento ou a prevenção da infecção por um patógeno de a/e, método para atenuar a virulência de um patógeno de a/e, método para a seleção de um composto que atenue a virulência de um patógeno e a/e, método para a produção de um polipeptìdio de patógeno de a/e, polipeptìdio recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, uso da composição e kit - Google Patents

composição, bactéria ou um preparado da mesma, método para detectar a presença de um patógeno de a/e em uma amostra, método para provocar uma resposta imunológica contra um patógeno de a/e ou um componente do mesmo em um animal, método para reduzir a colonização de um patógeno de a/e em um animal, método para reduzir a disseminação de um patógeno de a/e em um animal, método para o tratamento ou a prevenção da infecção por um patógeno de a/e, método para atenuar a virulência de um patógeno de a/e, método para a seleção de um composto que atenue a virulência de um patógeno e a/e, método para a produção de um polipeptìdio de patógeno de a/e, polipeptìdio recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, uso da composição e kit

Info

Publication number
BRPI0415816A
BRPI0415816A BRPI0415816-4A BRPI0415816A BRPI0415816A BR PI0415816 A BRPI0415816 A BR PI0415816A BR PI0415816 A BRPI0415816 A BR PI0415816A BR PI0415816 A BRPI0415816 A BR PI0415816A
Authority
BR
Brazil
Prior art keywords
pathogen
animal
virulence
composition
reducing
Prior art date
Application number
BRPI0415816-4A
Other languages
English (en)
Inventor
Brett Finlay
Samantha Gruenheid
Wanyin Deng
Bruce Vallance
Jose L Puente
Original Assignee
Univ British Columbia
Univ Mexico Nacional Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia, Univ Mexico Nacional Autonoma filed Critical Univ British Columbia
Publication of BRPI0415816A publication Critical patent/BRPI0415816A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

"COMPOSIçãO, BACTéRIA OU UM PREPARADO DA MESMA, MéTODO PARA DETECTAR A PRESENçA DE UM PATóGENO DE A/E EM UMA AMOSTRA, MéTODO PARA PROVOCAR UMA RESPOSTA IMUNOLóGICA CONTRA UM PATóGENO DE A/E OU UM COMPONENTE DO MESMO EM UM ANIMAL, MéTODO PARA REDUZIR A COLONIZAçãO DE UM PATóGENO DE A/E EM UM ANIMAL, MéTODO PARA REDUZIR A DISSEMINAçãO DE UM PATóGENO DE A/E EM UM ANIMAL, MéTODO PARA O TRATAMENTO OU A PREVENçãO DA INFECçãO POR UM PATóGENO DE A/E, MéTODO PARA ATENUAR A VIRULêNCIA DE UM PATóGENO DE A/E, MéTODO PARA A SELEçãO DE UM COMPOSTO QUE ATENUE A VIRULêNCIA DE UM PATóGENO DE A/E, MéTODO PARA A PRODUçãO DE UM POLIPEPTìDIO DE PATóGENO DE A/E, POLIPEPTìDIO RECOMBINANTE, MOLéCULA DE áCIDO NUCLéICO ISOLADA, VETOR, CéLULA HOSPEDEIRA, USO DA COMPOSIçãO E KIT". A invenção refere-se, em parte, a proteínas secretadas de patógenos bacterianos e aos métodos para o seu uso. Mais especificamente, a invenção apresenta, em parte, várias novas proteínas secretadas comuns para os patógenos de A/E. Em algumas realizações da invenção, esses polipeptídios e as moléculas de ácido nucléico que codificam esses polipeptídios, ou partes dos mesmos, são úteis como vacinas, diagnóstico, ou ferramentas de seleção de drogas para infecções patogênicas de A/E, ou como reagentes.
BRPI0415816-4A 2003-10-31 2004-10-29 composição, bactéria ou um preparado da mesma, método para detectar a presença de um patógeno de a/e em uma amostra, método para provocar uma resposta imunológica contra um patógeno de a/e ou um componente do mesmo em um animal, método para reduzir a colonização de um patógeno de a/e em um animal, método para reduzir a disseminação de um patógeno de a/e em um animal, método para o tratamento ou a prevenção da infecção por um patógeno de a/e, método para atenuar a virulência de um patógeno de a/e, método para a seleção de um composto que atenue a virulência de um patógeno e a/e, método para a produção de um polipeptìdio de patógeno de a/e, polipeptìdio recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, uso da composição e kit BRPI0415816A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51570303P 2003-10-31 2003-10-31
PCT/CA2004/001891 WO2005042746A1 (en) 2003-10-31 2004-10-29 Bacterial virulence factors and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0415816A true BRPI0415816A (pt) 2006-12-26

Family

ID=34549436

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415816-4A BRPI0415816A (pt) 2003-10-31 2004-10-29 composição, bactéria ou um preparado da mesma, método para detectar a presença de um patógeno de a/e em uma amostra, método para provocar uma resposta imunológica contra um patógeno de a/e ou um componente do mesmo em um animal, método para reduzir a colonização de um patógeno de a/e em um animal, método para reduzir a disseminação de um patógeno de a/e em um animal, método para o tratamento ou a prevenção da infecção por um patógeno de a/e, método para atenuar a virulência de um patógeno de a/e, método para a seleção de um composto que atenue a virulência de um patógeno e a/e, método para a produção de um polipeptìdio de patógeno de a/e, polipeptìdio recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, uso da composição e kit

Country Status (16)

Country Link
US (2) US8758771B2 (pt)
EP (3) EP2383287A1 (pt)
JP (2) JP5100122B2 (pt)
KR (3) KR20130018999A (pt)
CN (2) CN101711861A (pt)
AR (1) AR050050A1 (pt)
AU (2) AU2004286002B2 (pt)
BR (1) BRPI0415816A (pt)
CA (1) CA2543763A1 (pt)
MX (1) MXPA06004858A (pt)
NO (1) NO20062361L (pt)
NZ (1) NZ547156A (pt)
RU (2) RU2465331C2 (pt)
UA (1) UA94206C2 (pt)
WO (1) WO2005042746A1 (pt)
ZA (1) ZA200604412B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042746A1 (en) * 2003-10-31 2005-05-12 The University Of British Columbia Bacterial virulence factors and uses thereof
US9107864B2 (en) * 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US20090197249A1 (en) * 2004-11-01 2009-08-06 George Mason University Compositions and methods for diagnosing colon disorders
PT2016414E (pt) * 2006-05-05 2015-11-24 Opexa Therapeutics Vacina de células t
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
ES2335177B1 (es) * 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
GB0909198D0 (en) * 2009-05-28 2009-07-15 Queen Mary & Westfield College Methods and composition for treating NF-kappa B mediated disorders
WO2011005587A1 (en) * 2009-06-24 2011-01-13 University Of Dubuque Vaccine compositions and methods of use to protect against infectious disease
WO2011007350A2 (en) * 2009-07-13 2011-01-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Immunomodulatory agents and a tissue-targeted delivery system thereof for the treatment of immune-related disorders
EP2292799A1 (en) * 2009-08-11 2011-03-09 Agence Française de Securité Sanitaire des Aliments An assay for determining a molecular risk assessment of stec isolates
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
EP2620156B1 (en) 2010-08-23 2019-03-27 Kang Stem Biotech Co., Ltd. Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing stem cells treated with nod2 agonist or cultured product thereof
RU2497541C1 (ru) * 2012-07-20 2013-11-10 федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почётного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Фармацевтическая композиция на основе лигандов паттерн-распознающих рецепторов, способ ее использования в качестве иммуностимулятора для лечения инфекций, вызванных бактериальными и вирусными патогенами, способ ее использования в качестве адъюванта в составе вакцин
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9579370B2 (en) 2014-03-04 2017-02-28 The Board Of Regents Of The University Of Texas System Compositions and methods for enterohemorrhagic Escherichia coli (EHEC)vaccination
US10226520B2 (en) 2014-03-04 2019-03-12 The Board Of Regents Of The University Of Texa System Compositions and methods for enterohemorrhagic Escherichia coli (EHEC) vaccination
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN109180786B (zh) * 2015-11-20 2021-06-18 深圳市南山区人民医院 用于预防和治疗肠致病大肠杆菌感染的肽段
CN105821065A (zh) * 2016-04-29 2016-08-03 南方医科大学 一种双抗原重组蛋白及其制备方法和应用
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019147988A1 (en) * 2018-01-25 2019-08-01 Innate Biologics Llc Methods and compositions for use of recombinant bacterial effector proteins as anti-inflammatory agents
BR112020017257A2 (pt) * 2018-03-29 2020-12-22 Kimberly-Clark Worldwide, Inc. Sensor, artigo absorvente, e, método para indicar um potencial problema de pele ou gastrointestinal.
CN114401730A (zh) * 2019-05-01 2022-04-26 因内特生物制品有限责任公司 免疫调节组合物和方法
CN113174389B (zh) * 2021-05-27 2023-06-16 昆明理工大学 一种岷江百合诱导型启动子pr4及其应用
CN118910018B (zh) * 2024-07-31 2025-03-21 徐州医科大学 一种利用位点指引的突变形成技术增强NleC蛋白稳定性的优化方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310550A (en) 1979-10-26 1982-01-12 Pfizer Inc. Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
CA1247080A (en) * 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US5151267A (en) * 1988-07-15 1992-09-29 University Of Saskatchewan Bovine herpesvirus type 1 polypeptides and vaccines
SE9100556D0 (sv) * 1991-02-26 1991-02-26 Holmgren Jan Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans
US5370989A (en) * 1992-04-03 1994-12-06 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
RU2043771C1 (ru) * 1993-02-25 1995-09-20 Михаил Константинович Пирожков Вакцина против эшерихиоза животных
US5951988A (en) 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
ATE196773T1 (de) 1993-07-30 2000-10-15 Akzo Nobel Nv Infektiösen bronchitis virus 4/91 enthaltender geflügel-impfstoff
WO1996040861A1 (en) 1995-06-07 1996-12-19 Biolog, Inc. Microbiological media for isolation and identification of enteric pathogens such as e. coli and salmonella
FR2747394B1 (fr) 1996-04-15 1998-07-03 Rambach Alain Milieu de culture pour la mise en evidence des bacteries e. coli enterohemorragiques, et procede pour sa mise en evidence
ES2389625T3 (es) 1996-04-23 2012-10-29 The University Of British Columbia Vacuna que comprende la proteína EspA asociada a Escherichia coli patógena
JP2001520009A (ja) 1997-10-16 2001-10-30 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 鳥の導入遺伝子についてのマグナム特異的プロモーターを含むベクター
PT1029054E (pt) 1997-11-12 2009-11-11 Univ British Columbia Hp90: receptor membranar do hospedeiro para bactérias patogénicas codificado pelo gene bacteriano tir
US7208574B1 (en) * 1997-11-12 2007-04-24 The University Of British Columbia Host receptor for pathogenic bacteria
US6365723B1 (en) * 1998-12-04 2002-04-02 Wisconsin Alumni Research Foundation Sequences of E. coli O157
US20020132788A1 (en) 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US20020173478A1 (en) 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
NZ527322A (en) * 2001-01-04 2005-07-29 Univ Saskatchewan EHEC cell culture supernatant vaccine
JP2002355074A (ja) 2001-01-24 2002-12-10 Univ Tsukuba 腸管出血性病原性大腸菌ｏ１５７：ｈ７に特異的な核酸分子およびポリペプチド並びにこれらの使用方法
TWI350174B (en) * 2003-03-12 2011-10-11 Wyeth Corp Adjuvanted bovine vaccines
WO2005042746A1 (en) 2003-10-31 2005-05-12 The University Of British Columbia Bacterial virulence factors and uses thereof

Also Published As

Publication number Publication date
JP5100122B2 (ja) 2012-12-19
ZA200604412B (en) 2007-09-26
KR20110102956A (ko) 2011-09-19
EP1692287A4 (en) 2007-03-28
AU2011201889A1 (en) 2011-05-19
CN101711861A (zh) 2010-05-26
UA94206C2 (ru) 2011-04-26
CA2543763A1 (en) 2005-05-12
EP1692287A1 (en) 2006-08-23
AU2004286002A1 (en) 2005-05-12
US20070041997A1 (en) 2007-02-22
AU2004286002B2 (en) 2011-01-27
NZ547156A (en) 2009-08-28
CN1922324B (zh) 2010-06-09
JP2011250790A (ja) 2011-12-15
US8758771B2 (en) 2014-06-24
CN1922324A (zh) 2007-02-28
AR050050A1 (es) 2006-09-27
RU2006118803A (ru) 2007-12-10
KR101242445B1 (ko) 2013-03-15
RU2465331C2 (ru) 2012-10-27
EP2383287A1 (en) 2011-11-02
EP2462948A1 (en) 2012-06-13
NO20062361L (no) 2006-07-20
JP2007531511A (ja) 2007-11-08
RU2012122559A (ru) 2013-12-10
KR20130018999A (ko) 2013-02-25
US20120064572A1 (en) 2012-03-15
KR20070031848A (ko) 2007-03-20
US8507249B2 (en) 2013-08-13
WO2005042746A1 (en) 2005-05-12
AU2011201889B2 (en) 2013-04-04
MXPA06004858A (es) 2007-04-16

Similar Documents

Publication Publication Date Title
BRPI0415816A (pt) composição, bactéria ou um preparado da mesma, método para detectar a presença de um patógeno de a/e em uma amostra, método para provocar uma resposta imunológica contra um patógeno de a/e ou um componente do mesmo em um animal, método para reduzir a colonização de um patógeno de a/e em um animal, método para reduzir a disseminação de um patógeno de a/e em um animal, método para o tratamento ou a prevenção da infecção por um patógeno de a/e, método para atenuar a virulência de um patógeno de a/e, método para a seleção de um composto que atenue a virulência de um patógeno e a/e, método para a produção de um polipeptìdio de patógeno de a/e, polipeptìdio recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, uso da composição e kit
Lun et al. Role of suilysin in pathogenesis of Streptococcus suis capsular serotype 2
Vytvytska et al. Identification of vaccine candidate antigens of Staphylococcus aureus by serological proteome analysis
Fajardo Bonin et al. Identification of immunogenic proteins of the bacterium Acinetobacter baumannii using a proteomic approach
MA29678B1 (fr) Nouvelle methode de prevention ou de traitement d'une infection par m tuberculosis
BR0207068A (pt) Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus
UY26783A1 (es) Antígenos de estreptococo.
EA201001212A1 (ru) Лечение микробных инфекций
FI84431C (fi) Foerfarande foer framstaellning av ett fibronektinbindande cellyteprotein.
EP0694309A2 (en) Vaccine, antigens and antibodies containing compound for inhibiting and preventing induced staphylococcus infection
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
Rossi et al. The oral microbiota of domestic cats harbors a wide variety of Staphylococcus species with zoonotic potential
Lee et al. Susceptibilities against bovine lactoferrin with microorganisms isolated from mastitic milk
Esmaeilkhani et al. In vivo validation of the immunogenicity of recombinant baumannii acinetobactin utilization a protein (rBauA)
Kathirvel et al. Enhancement of the pathogenicity of Staphylococcus aureus strain Newman by a small noncoding RNA SprX1
Li et al. Host avian beta-defensin and toll-like receptor responses of pigeons following infection with pigeon paramyxovirus type 1
Kolybo et al. Immunobiology of diphtheria. Recent approaches for the prevention, diagnosis, and treatment of disease
Prasannavadhana et al. Outer Membrane Proteome Analysis of Indian Strain of Pasteurella multocida Serotype B: 2 by MALDI‐TOF/MS Analysis
Puangpetch et al. Comparison of the protective effects of killed Burkholderia pseudomallei and CpG oligodeoxynucleotide against live challenge
Magaš et al. Efficiency evaluation of a bivalent vaccine in the prophylaxis of mastitis in cows
Çiftci et al. Development and validation of glycoprotein‐based native‐subunit vaccine for fish against A eromonas hydrophila
Cavaco et al. A novel C5a-derived immunobiotic peptide reduces Streptococcus agalactiae colonization through targeted bacterial killing
US20100055123A1 (en) Vaccine against burkholderia infections
Bache et al. Bordetella Pertussis Toxin does not induce the release of pro-inflammatory cytokines in human whole blood
DE60035485D1 (de) IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2330 DE 01-09-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.